Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.

CONCLUSIONS: Oncotype DX was the only gene expression test that was estimated to reduce costs versus standard care in Germany. The reimbursement of Oncotype DX testing in standard clinical practice in Germany should be considered.
PMID: 29128582 [PubMed - as supplied by publisher]

Source: Breast - November 9, 2017 Category: Cancer & Oncology Authors: Lux MP, Nabieva N, Hildebrandt T, Rebscher H, Kümmel S, Blohmer JU, Schrauder MG Tags: Breast Source Type: research